Clinical Trial

With a key FDA decision looming, Orca Bio's massive new funding aims to commercialize a therapy that could make curative transplants safer for more patients.

With a huge new investment, MEDIPOST is advancing its proven stem cell therapy for knee osteoarthritis into a pivotal Phase III trial in the United States.

With new funding and a veteran biotech leader, Montreal's Find Therapeutics advances its first-in-class therapy aimed at reversing nerve damage in MS.

A new AI-designed vaccine, TG4050, has prevented relapse in all head and neck cancer patients in a key trial, signaling a breakthrough in personalized medicine.

Ventyx Biosciences is under investigation for misleading investors after a trial delay caused a 15% stock drop, even as a pharma giant moves to acquire it.

Alessa Therapeutics’ rice-sized implant, Enolen, earns FDA Fast Track, promising a new era for prostate cancer therapy without debilitating side effects.

New research reveals a stark disconnect between clinical views and patient reality in atopic dermatitis, with millions suffering severe, overlooked impacts.

With key studies now complete, Biofrontera's light-based therapy Ameluz could soon offer a new weapon against widespread actinic keratosis and stubborn acne.

A new class of painkillers promises the power of opioids with a far lower risk of addiction. Tris Pharma's cebranopadol could reshape pain management.

NeuroSense adds world-renowned expert Prof. Steven Arnold to its board, a major vote of confidence in its multi-target Alzheimer's drug, PrimeC.

With a major cash infusion and key pipeline milestones, Xilio Therapeutics validates its tumor-activated approach to fighting cancer and extends its runway to 2027.

Positive early human safety data for its lead drug and new candidates for Rett syndrome and MASH signal a pivotal year for ProQR's Axiomer technology.

A new study on a compact, wireless robotic device could democratize access to precision knee surgery, thanks to pioneering work from a rural Missouri surgeon.

With a key FDA meeting set, Trevi Therapeutics pushes its drug Haduvio into late-stage trials, offering hope for millions with no approved treatments.

A new vectorized antibody therapy for ALS, VTx-002, has been granted FDA Fast Track status, accelerating its path to patients battling the disease.

Rani Therapeutics starts Phase 1 trials for an oral obesity drug, challenging the injectable market with a novel delivery system and a dual-action compound.

China approves Aizhida, a novel once-daily ADHD medication. Its unique dual-action formula provides rapid and sustained symptom control, aiming to transform treatment.

A newly validated genetic test accurately predicts melanoma risk, offering a non-invasive alternative to the standard surgical biopsy for many patients.

Azafaros presents its promising drug, nizubaglustat, for untreatable rare neurological disorders, backed by major funding and late-stage clinical trials.

Interim results from the SPARTAN study reveal a novel lateral-oblique SI joint fusion system offers significant pain reduction and improved function.